New weight loss drug shows promise in Long-Term Follow-Up study
NCT ID NCT06671821
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at the long-term safety and effectiveness of the drug HRS-7535 for weight management in 81 adults with obesity who had already completed a 36-week treatment course. Participants took the drug for an additional 32 weeks to see how well it helped maintain weight loss and whether any side effects appeared. The goal is to see if HRS-7535 can be a safe and effective long-term option for managing obesity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-7535 (a drug tablet for weight loss)
What this could lead to
If successful, this could support HRS-7535 as a long-term weight management option for obesity, potentially helping people achieve and maintain significant weight loss.
What could go wrong
This is a small, completed Phase 2 extension study with only 81 participants. Long-term safety and efficacy are still being evaluated, and results may not apply to all people with obesity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100039, China